<DOC>
	<DOC>NCT01508949</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.</brief_summary>
	<brief_title>Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes mellitus Diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide HbA1c for diet treated subjects 6.512%, both inclusive HbA1c for sulphonylurea or repaglinide treated subjects maximum 10% Body mass index (BMI) at least 27 kg/m^2 Euthyroid subjects Fasting blood glucose 714 mmol/l Impaired liver function Impaired renal function Cardiac problems Uncontrolled treated/untreated hypertension Recurrent severe hypoglycaemia as judged by the Investigator Known or suspected allergy to trial product or related products Use of any drug (except for OHAs (oral hypoglycaemic agents), which in the Investigator's opinion could interfere with the glucose level or body weight. Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>